Queerty is better as a member
This isn’t news … The news from the conference is Sangamo’s “Functional Cure” for HIV/AIDS which is getting virtually no coverage.
Tiny Sangamo BioSciences Inc.’s potential “functional cure” for HIV is getting big attention in advance of a major AIDS scientific meeting.
SB-728-T, a gene therapy designed to knock out the CCR5 receptor on CD4 cells, protects and increases CD4s in patients experiencing poor immunologic recovery while on antiretroviral (ARV) therapy, according to preliminary Phase I study data reported on Monday, February 28, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. The new results, reported by Jay Lalezari, MD, are among the first from a human study illustrating the therapeutic—and curative—potential of this novel approach being developed by Sangamo BioSciences.
Need an account? Register It's free and easy.
PHOTOS: A Look Back At Our Top 10 Olympic Crushes Of 2016
PHOTOS: Gymnast Danell Leyva Shows Off His Medals And Much, Much More
PHOTOS: Tennis Star Grigor Dimitrov Knows How To Serve And Receive
PHOTOS: Tropical Heat Engulfs Key West, But Who Has The Tiniest Swimsuit?
PHOTOS: What We Wouldn't Give To Be Wrestler Jordan Burroughs' Singlet For A Day